UBS Group cut shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a buy rating to a neutral rating in a report issued on Friday, 99wallstreet.com reports. They currently have $18.00 price target on the biopharmaceutical company’s stock.
Several other brokerages also recently commented on SCMP. B. Riley downgraded shares of Sucampo Pharmaceuticals from a buy rating to a neutral rating and set a $18.00 price objective for the company. in a research report on Tuesday, December 26th. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Sunday, December 31st. Maxim Group downgraded shares of Sucampo Pharmaceuticals to a hold rating in a research report on Monday, January 1st. Leerink Swann restated a market perform rating and set a $15.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Tuesday, January 2nd. Finally, Mizuho restated a neutral rating and set a $18.00 price objective (up from $14.00) on shares of Sucampo Pharmaceuticals in a research report on Wednesday, January 3rd. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $21.58.
Sucampo Pharmaceuticals (SCMP) traded up $0.35 during midday trading on Friday, hitting $18.40. 5,267,400 shares of the stock were exchanged, compared to its average volume of 4,882,520. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.75. The firm has a market capitalization of $851.38, a P/E ratio of -5.59, a price-to-earnings-growth ratio of 5.07 and a beta of 1.45.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. During the same period in the previous year, the business earned $0.30 earnings per share. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. research analysts predict that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.
In other news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.13% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in SCMP. Schwab Charles Investment Management Inc. increased its holdings in shares of Sucampo Pharmaceuticals by 36.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 246,796 shares of the biopharmaceutical company’s stock worth $2,592,000 after buying an additional 66,493 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Sucampo Pharmaceuticals by 1.6% during the second quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 200 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Sucampo Pharmaceuticals by 0.9% during the second quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 423 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Sucampo Pharmaceuticals during the second quarter worth $199,000. Finally, SG Americas Securities LLC increased its holdings in shares of Sucampo Pharmaceuticals by 5.6% during the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 631 shares in the last quarter. Institutional investors own 65.29% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “UBS Group Lowers Sucampo Pharmaceuticals (SCMP) to Neutral” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2018/01/09/ubs-group-lowers-sucampo-pharmaceuticals-scmp-to-neutral.html.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.